Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations

被引:56
|
作者
da Costa, Roner F. [2 ]
Freire, Valder N. [2 ]
Bezerra, Eveline M. [3 ]
Cavada, Benildo S. [4 ]
Caetano, Ewerton W. S. [1 ]
de Lima Filho, Jose L. [5 ]
Albuquerque, Eudenilson L. [6 ]
机构
[1] Inst Fed Educ Ciencia & Tecnol Ceara, BR-60040531 Fortaleza, Ceara, Brazil
[2] Univ Fed Ceara, Dept Fis, BR-60455760 Fortaleza, Ceara, Brazil
[3] Univ Fed Ceara, Fac Med, BR-62042280 Sobral, Brazil
[4] Univ Fed Ceara, Dept Bioquim, BR-60455760 Fortaleza, Ceara, Brazil
[5] Univ Fed Pernambuco, Lab Imunopatol Keizo Azami, BR-50670901 Recife, PE, Brazil
[6] Univ Fed Rio Grande do Norte, Dept Biofis & Farmacol, BR-59072970 Natal, RN, Brazil
关键词
D O I
10.1039/c1cp22824b
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
By taking advantage of the crystallographic data of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) complexed with statins, a quantum biochemistry study based on the density functional theory is performed to estimate the interaction energy for each statin when one considers binding pockets of different sizes. Assuming a correlation between statin potency and the strength of the total HMGR-statin binding energy, clinical data as well as IC50 values of these cholesterol-lowering drugs are successfully explained only after stabilization of the calculated total binding energy for a larger size of the ligand-interacting HGMR region, one with a radius of at least 12.0 angstrom. Actually, the binding pocket radius suggested by classic works, which was based solely on the interpretation of crystallographic data of the HMGR-statin complex, is smaller than that necessary to achieve total binding energy convergence in our simulations. Atorvastatin and rosuvastatin are shown to be the most strongly bound HMGR inhibitors, while simvastatin and fluvastatin are the weakest ones. A binding site, interaction energy between residues and statin atoms, and residues domain (BIRD) panel is constructed, indicating clear quantum biochemistry-based routes for the development of new statin derivatives.
引用
下载
收藏
页码:1389 / 1398
页数:10
相关论文
共 50 条
  • [1] Statin Inhibition of HMG-CoA Reductase by Quantum Biochemistry Computations
    Fulco, U. L.
    Albuquerque, E. L.
    da Silva, L. R.
    29TH SOUTHERN BIOMEDICAL ENGINEERING CONFERENCE (SBEC 2013), 2013, : 159 - +
  • [2] Structural mechanism for statin inhibition of HMG-CoA reductase
    Istvan, ES
    Deisenhofer, J
    SCIENCE, 2001, 292 (5519) : 1160 - 1164
  • [3] Statin inhibition of HMG-CoA reductase: a 3-dimensional view
    Istvan, E
    ATHEROSCLEROSIS SUPPLEMENTS, 2003, 4 (01) : 3 - 8
  • [4] Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
    Wurtz, Peter
    Wang, Qin
    Soininen, Pasi
    Kangas, Antti J.
    Fatemifar, Ghazaleh
    Tynkkynen, Tuulia
    Tiainen, Mika
    Perola, Markus
    Tillin, Therese
    Hughes, Alun D.
    Mantyselka, Pekka
    Kahonen, Mika
    Lehtimaki, Terho
    Sattar, Naveed
    Hingorani, Aroon D.
    Casas, Juan-Pablo
    Salomaa, Veikko
    Kivimaki, Mika
    Jarvelin, Marjo-Riitta
    Smith, George Davey
    Vanhala, Mauno
    Lawlor, Debbie A.
    Raitakari, Olli T.
    Chaturvedi, Nish
    Kettunen, Johannes
    Ala-Korpela, Mika
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (10) : 1200 - 1210
  • [5] BIOCHEMISTRY AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    ATHEROSCLEROSIS VIII, 1989, 817 : 775 - 780
  • [6] Newer HMG-CoA reductase inhibitor (statin) therapies
    Brinton, EA
    CLINICAL CARDIOLOGY, 2001, 24 (07) : II10 - II13
  • [7] CHEMISTRY, BIOCHEMISTRY, AND PHARMACOLOGY OF HMG-COA REDUCTASE INHIBITORS
    ENDO, A
    KLINISCHE WOCHENSCHRIFT, 1988, 66 (10): : 421 - 427
  • [8] INHIBITION OF DEGRADATION OF HMG-COA REDUCTASE BY MEVINOLIN
    SINENSKY, M
    LOGEL, J
    JOURNAL OF LIPID RESEARCH, 1983, 24 (10) : 1413 - 1413
  • [10] Impact of HMG-CoA reductase inhibition on brain pathology
    Zipp, Frauke
    Waiczies, Sonia
    Aktas, Orhan
    Neuhaus, Oliver
    Hemmer, Bernhard
    Schraven, Burkhard
    Nitsch, Robert
    Hartung, Hans-Peter
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2007, 28 (07) : 342 - 349